The medtech giant plans to use this system to streamline implantation for electrodes use with its Proclaim DRG neurostimulation system. It designed its new system to streamline the procedure when doctors implant them in patients suffering from complex regional pain syndrome (CRPS) Type 1 and causalgia (CRPS Type 2) of the lower extremities.

Proclaim DRG targets and stimulates the dorsal root ganglion (DRG) cluster of nerve cells found along the spine. This cluster controls pain signals from specific areas of the body, including the pelvis, groin, hip, knee, ankle and foot. Proclaim DRG is the first and only DRG technology approved to treat CRPS of the lower limbs, Abbott said in a news release. It also picked up expanded MRI labeling in January 2024.